Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma

Pathology International

Volumn 54, Issue 9, 2004, Pages 675-681

  Goto, Akiteru ^a   Niki, Toshiro ^a   Moriyama, Sachiko ^b   Funata, Nobuaki ^b   Moriyama, Hirokazu ^b   Nishimura, Yoshihiro ^b   Tsuchida, Rika ^c   Kato, Jun Ya ^d   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Atypical adenomatous hyperplasia; Jab1; Ki 67; Lung adenocarcinoma; P27 (kip1); Prognosis; Skp2

Indexed keywords

CARRIER PROTEIN; KI 67 ANTIGEN; PROTEIN JAB1; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD VESSEL; BRONCHUS MUCOSA; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LYMPH VESSEL; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE HYDROLASES; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 4644259385     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2004.01679.x     Document Type: Article

References (27)

1. Gupta AK, Harris EER, Bernhard EJ et al. Overview of cell cycle and apoptosis. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, eds. Lung Cancer Principles and Practice. Philadelphia: Lippincott Williams & Wilkins, 2000; 5-67.
2. Forgacs E, Zochbauer-Muller S, Olah E, Minna JD. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 2001; 7: 6-13.
3. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 1998; 153: 963-72.
4. Kawabuchi B, Moriyama S, Hironaka M et al. p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. Int J Cancer 1999; 84: 49-53.
5. Esposito V, Baldi A, De Luca A et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381-5.
6. Hayashi H, Ito T, Yazawa T et al. Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma. J Pathol 2000; 192: 26-31.
7. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
8. Kawamata N, Morosetti R, Miller CW et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 1995; 55: 2266-9.
9. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-9.
10. Sutterluty H, Chatelain E, Marti A et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207-14.
11. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999; 398: 160-65.
12. Tomoda K, Kubota Y, Arata Y et al. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex. J Biol Chem 2002; 277: 2302-10.
13. Yokoi S, Yasui K, Saito-Ohara F et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161: 207-16.
14. Gstaiger M, Jordan R, Lim M et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98: 5043-8.
15. Masuda TA, Inoue H, Sonoda H et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62: 3819-25.
16. Seki R, Okamura T, Koga H et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 2003; 73: 230-35.
17. Tsuchida R, Miyauchi J, Shen L et al. Expression of cyclin-dependent kinase inhibitor p27/Kip1 and AP-1 coactivator p38/Jab1 correlates with differentiation of embryonal rhabdomyosarcoma. Jpn J Cancer Res 2002; 93: 1000-6.
18. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27 (Kip1). Cancer Res 2003; 63: 2977-81.
19. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 1999; 111: 610-22.
20. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-17.
21. The Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer. Tokyo, Japan: Kanehara & Co., Ltd; 1999.
22. Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001; 125: 87-99.
23. Wan M, Cao X, Wu Y et al. Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep 2002; 3: 171-6.
24. Bae MK, Ahn MY, Jeong JW et al. Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 2002; 277: 9-12.
25. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 1998.
26. Mori M, Mimori K, Shiraishi T et al. P27 expression and gastric carcinoma. Nat Med 1997; 3: 593.
27. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10-17.